

RESEARCH

Open Access



The impact of seasonal variation on the composition of the volatile oil of *Polyalthia suberosa* (Roxb.) Thwaites leaves and evaluation of its acetylcholinesterase inhibitory activity

Orchid A. Mahmoud¹ , Iriny M. Ayoub¹ , Omayma A. Eldahshan^{1,2*}  and Abdel Nasser B. Singab^{1,2*} 

Abstract

Background *Polyalthia suberosa* (Roxb.) Thwaites (Annonaceae) is a medicinal plant that has been reported for its various pharmacological potentials, such as its anti-inflammatory, analgesic, antioxidant, and neuropharmacological activities. This study aimed to analyze the leaf essential oils of *P. suberosa* (PSLO) collected in different seasons, to evaluate the acetylcholinesterase inhibitory activity, and to corroborate the obtained results via *in-silico* molecular docking studies.

Methods The leaf essential oils of *P. suberosa* collected in different seasons were analyzed separately by GC/MS. The acetylcholinesterase inhibitory activity of the leaves oil was assessed via colorimetric assay. *In-silico* molecular docking studies were elucidated by virtual docking of the main compounds identified in *P. suberosa* leaf essential oil to the active sites in human acetylcholinesterase crystal structure.

Results A total of 125 compounds were identified where D-limonene (0.07 – 24.7%), α -copaene (2.25 – 15.49%), E- β -caryophyllene (5.17 – 14.42%), 24-noroleana-3,12-diene (12.92%), β -pinene (0.14 – 8.59%), and α -humulene (2.49–6.9%) were the most abundant components. Results showed a noteworthy influence of the collection season on the chemical composition and yield of the volatile oils. The tested oil adequately inhibited acetylcholinesterase enzyme with an IC₅₀ value of 91.94 μ g/mL. Additionally, *in-silico* molecular docking unveiled that palmitic acid, phytol, *p*-cymene, and caryophyllene oxide demonstrated the highest fitting scores within the active sites of human acetylcholinesterase enzyme.

Conclusions From these findings, it is concluded that *P. suberosa* leaf oil should be evaluated as a food supplement for enhancing memory.

Keywords Acetylcholinesterase, Alzheimer's disease, Seasonal variation, *Polyalthia suberosa*, Volatile oil

*Correspondence:
Omayma A. Eldahshan
oeldahshan@pharma.asu.edu.eg
Abdel Nasser B. Singab
dean@pharma.asu.edu.eg

¹Department of Pharmacognosy, Faculty of Pharmacy, Ain Shams University, 11566-Abbassia, Cairo, Egypt

²Center for Drug Discovery Research and Development, Faculty of Pharmacy, Ain Shams University, Cairo 11566, Egypt



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Introduction

Alzheimer's disease (AD) is one of the challenging disorders of our century and is the root cause of dementia. Throughout the world, about 40 million people suffer from dementia, and this number is supposed to double as much every 20 years until approximately 2050 [1]. AD is a progressive, multifactorial, and neurodegenerative disorder. The pathology of AD may be attributed to several factors such as extracellular deposition of A β peptide and the intracellular aggregation of tau protein. In addition, the significant decrease in the neurotransmitter acetylcholine (ACh) in the brain is associated with the advancement of AD. Therefore, the enhancement of the central cholinergic function by acetylcholinesterase inhibition is one of the powerful ways to treat AD [2, 3]. Rivastigmine and tacrine, common drugs against AD possessing acetylcholinesterase (AChE) inhibitory activity, are reported to exert numerous side effects such as liver toxicity, nausea, and diarrhea [2]. Nature has provided us with foods and phytoconstituents that are valuable to human health. Nowadays, natural products attained much interest and played essential roles in the treatment of many diseases [4, 5]. In this context, galantamine isolated from plant source has been used as an AChE inhibitor in several countries with mild side effects [6].

Genus *Polyalthia*, belonging to family Annonaceae, comprises more than 100 species widely distributed in tropical and subtropical regions, including South Asia, South East Asia, and Australia [7]. Traditionally, *P. longifolia* has been used to treat many ailments such as fever, headache, high blood pressure, diabetes, and infections [8]. Fruits of *P. suberosa* have been used as anti-diarrheal. The leaves have been used to treat colds and coughs, and the barks have been used as analgesic [9]. Reported biological activities include antioxidant, anti-inflammatory, anticancer, antibacterial, and antiviral [7, 10, 11].

Polyalthia suberosa (Roxb.) Thwaites is an evergreen shrub traditionally used as laxative, abortifacient, analgesic, and in treatment of numerous skin infections. It was reported that different extracts of *P. suberosa* exerted anti-inflammatory, analgesic, anti-bacterial, antioxidant, and neuropharmacological activities [9, 10]. Despite the biological importance of this plant, the isolated essential oil from the leaves wasn't fully investigated, only the cytotoxic and antimicrobial activities have been studied [12].

The chemical composition of plants is known to be affected by various extrinsic factors including climate, phenological phases, altitude, and soil. Thus, the chemical composition of essential oils and biological activity, which is dependent on the composition, are susceptible to variations [13, 14].

The present study was designed to investigate the composition of the volatile oils isolated from *P. suberosa*

fresh leaves (PSLO), cultivated in Egypt, by Gas Chromatography/Mass Spectrometry (GC/MS) and the effect of seasonal variation on the yield and composition of these volatiles was assessed. Furthermore, the acetylcholinesterase inhibitory activity was evaluated. In addition, molecular docking was implemented to evaluate the binding affinities between the major oil components and acetylcholinesterase enzyme. ADMET prediction was carried out to evaluate the pharmacokinetics, pharmacodynamics, and toxicity properties of the identified compounds. This can help understand the possible use of PSLO as acetylcholinesterase inhibitor for incorporating this oil in formulations to treat AD.

Materials and methods

Plant material

The fresh leaves of *P. suberosa* were collected from Zoo Garden, Giza, Egypt; and was identified and authenticated by Mrs Therese Labib, Plant Taxonomy Consultant at Ministry of Agriculture and El-Orman Botanical Garden, Giza, Egypt. Leaves were collected in four seasons (2019 and 2020); namely winter (January), spring (April), summer (August), and autumn (November). A voucher specimen of the plant (PHG-P-PS-297) was stored at the Pharmacognosy Department, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.

Isolation of volatile constituents

Fresh leaves of *P. suberosa* (200 g), collected in four different seasons, were exposed to six hours of hydrodistillation using a Clevenger-type apparatus. The oil yields were measured in %w/w based on the initial weight of the plant. The oils were kept for further analysis in sealed vials at 4 °C.

GC/MS analysis

GC/MS analysis was carried out using Shimadzu GC/MS-QP 2010 (Kyoto, Japan) supplied with Rtx-5MS capillary column (30 m x 0.25 mm i.d. x 0.25 μ m film thickness) (Restek, USA). The initial oven temperature was kept at 45 °C for 2 min (isothermal), then heated to 300 °C at a rate of 5 °C/min and kept constant at 300 °C for 5 min (isothermal). The injector temperature was held at 250 °C. The used carrier gas was helium using a constant flow rate of 1.41 mL/min. An auto sampler was used to inject the sample (1 μ L) and the split ratio was 15:1. The MS conditions were as follows: (equipment current) filament emission current: 60 mA, ion source temperature: 200 °C, ionization voltage: 70 eV and scan range: 35–500 amu [15].

Identification of volatile constituents

Identification of volatile constituents was achieved by comparison of their retention indices, their mass spectra

and fragmentation patterns with the National Institute of Standards and Technology (NIST-17) database, Adams, and literature [16–25]. Retention indices (RI) were deduced relative to a homologous series of n-alkanes (C8–C28) injected under the same conditions as the essential oils [26].

Acetylcholinesterase inhibitory activity

Acetylcholinesterase inhibitory activity was assessed according to the method of Ellman et al. [27] with some modifications. AChE was obtained from *Electrophorus electricus*. 3,3'-Dithiodipropionic acid di-(N-hydroxy-succinimide ester) (DTNB) was used as an indicator. The indicator solution (10 μ L) was transferred to a 96-well plate, followed by 20 μ L of the enzyme solution, then 20 μ L of oil samples at a concentration range of (100–5 μ g/mL) were added. Afterwards, 10 μ L of the substrate acetylcholine iodide was added to all wells. The plate was incubated in a dark chamber for 20 min at room temperature. At the end of the incubation period, the color was measured at 412 nm using a microplate reader. Donepezil was used as a positive control. Percentage inhibition was calculated using this formula:

$$\text{Percentage inhibition} = \frac{(\text{Absorbance of control} - \text{absorbance of sample})}{\text{Absorbance of control}} \times 100$$

IC₅₀ (concentration of sample used to inhibit 50% of acetylcholinesterase under the test conditions) was calculated as previously reported [27, 28].

Statistical analysis

Data was presented as mean \pm SD of three measurements. The IC₅₀ values were calculated by Microsoft Excel 2010 (level of significance $p < 0.05$).

In-silico molecular docking study

Molecular docking study

Cholinesterase inhibitory activity was further elucidated by virtual docking of the main compounds identified in PSLO to the active sites in human acetylcholinesterase (PDB ID: 4EY7, 2.35 Å) crystal structure, using Discovery Studio 2.5 (Accelrys Inc., San Diego, CA, USA). The complex of the human acetylcholinesterase crystal structure with donepezil, a pharmacologically active Alzheimer's disease drug, was retrieved from the Protein Data Bank (<http://www.rcsb.org/pdb/>), accessed on 23rd October 2023. Donepezil, the co-crystallized inhibitor, was employed to identify the active binding sites in the AChE enzyme. The ligand was taken out before the docking simulations. Discovery Studio 4.5 (Accelrys Inc., San Diego, CA, USA) was utilized acquiring the C-docker protocol as previously described [15, 29–32]. To verify C-Docker as a docking algorithm, donepezil was removed

from 4EY7, after that it was superimposed on the docked pose of the co-crystallized inhibitor and finally the root mean square deviation (RMSD) was calculated.

ADMET predictions

Absorption, distribution, metabolism, excretion, and toxicity (ADMET) were predicted for the main compounds identified in PSLO implementing ADMET prediction protocol in Discovery Studio 4.5 (Accelrys Inc., San Diego, CA, USA).

Results and discussion

GC/MS analysis

The essential oils of *P. suberosa* fresh leaves were prepared using hydrodistillation technique. All volatile oil samples were light yellow in color, displaying a characteristic odor. The oil yields of summer, autumn, winter, and spring were 0.03, 0.04, 0.02, and 0.07%w/w, respectively. The highest yield was obtained from leaves collected during spring (0.07%w/w) followed by summer (0.03%w/w) while the lowest yield was obtained during winter (0.02%w/w).

GC/MS analyses of the volatile oil samples showed distinctive qualitative and quantitative differences. A meticulous comparative analysis of the oils is described in Table 1. The chemical structures of the major compounds are shown in Fig. 1. Identified compounds for the different samples accounted for 96.52, 85.5, 95.79, and 81.92% of the total composition in summer, autumn, winter, and spring seasons, respectively. A total of 125 compounds belonging to different classes were identified by comparing their mass fragmentation patterns and retention indices to the reported data and NIST library. A bar chart of the different components of *P. suberosa* volatile oils was constructed to show the qualitative and quantitative differences among the volatile samples (Fig. 2). GC/MS chromatograms of the leaves volatile oils of different seasons are shown in Fig. S1.

The identified compounds were classified into eight classes; as shown in Fig. 3 with sesquiterpene hydrocarbons being the most abundant class, ranging from 21.53 to 56.62% of the total volatile oils composition, where, the highest concentration was found in summer volatile oil (56.62%), followed by spring volatile oil (46.89%), then winter volatile oil (22.2%), and the lowest concentration was found in autumn volatile oil (21.53%). This finding was in accordance with previous reports, where sesquiterpene hydrocarbons (52.9–84.8%) were the predominant constituents of *P. sumatrana*, *P. stenopetalla*, *P. cauliflora*, and *P. rumphii* [33].

α -Copaene (2.25–15.49%), E- β -caryophyllene (5.17–14.42%), α -humulene (2.49–6.9%), bicyclogermacrene (1.58–5.57%), and δ -cadinene (1.86–4.93%) were the most abundant compounds of sesquiterpene

Table 1 Chemical profile of *Polyalthia suberosa* volatile oils in four different seasons

Peak no.	Rt	Compound	Molecular formula	RI _{exp}	RI _{lit}	Content (%)				Identification
						Summer	Autumn	Winter	Spring	
1	7.32	α -Pinene	C ₁₀ H ₁₆	917	917	3.17	1.28	0.99	0.03	RI, MS
2	7.75	Camphene	C ₁₀ H ₁₆	931	930	0.12	-	-	-	RI, MS
3	8.554	Sabinene	C ₁₀ H ₁₆	961	961	-	0.16	2.77	0.03	RI, MS
4	8.65	β-Pinene	C ₁₀ H ₁₆	964	964	8.59	3.4	2.13	0.14	RI, MS
5	9.125	β -Myrcene	C ₁₀ H ₁₆	981	981	1.36	0.56	0.65	-	RI, MS
6	9.67	β -cis-Ocimene	C ₁₀ H ₁₆	1001	1002	-	-	2.47	-	RI, MS
7	9.88	2- Carene	C ₁₀ H ₁₆	1007	1007	-	-	1.18	-	RI, MS
8	10.025	2,6-Dimethyl nonane	C ₁₁ H ₂₄	1012	1022	-	-	0.32	-	RI, MS
9	10.15	<i>p</i> -Cymene	C ₁₀ H ₁₄	1016	1016	0.37	-	0.35	0.02	RI, MS
10	10.266	D-Limonene	C ₁₀ H ₁₆	1020	1020	2.63	0.74	24.7	0.07	RI, MS
11	10.9	β -Ocimene	C ₁₀ H ₁₆	1040	1040	1.04	2.77	1.11	0.03	RI, MS
12	11.105	5-Methyl decane	C ₁₁ H ₂₄	1047	1056	-	-	0.89	-	RI, MS
13	11.21	γ -Terpinene	C ₁₀ H ₁₆	1050	1050	0.44	-	2.26	-	RI, MS
14	12.155	Terpinolene	C ₁₀ H ₁₆	1081	1081	0.2	-	0.64	-	RI, MS
15	12.5	Linalool	C ₁₀ H ₁₈ O	1092	1092	-	-	-	0.25	RI, MS
16	12.595	Nonanal	C ₉ H ₁₈ O	1095	1094	0.53	-	-	0.03	RI, MS
17	14.9	Thujol	C ₁₀ H ₁₈ O	1169	1165	-	-	-	0.29	RI, MS
18	15.335	α -Terpineol	C ₁₀ H ₁₈ O	1183	1183	-	-	-	0.08	RI, MS
19	16.17	β -Cyclocitral	C ₁₀ H ₁₆ O	1211	1210	0.17	-	-	-	RI, MS
20	16.47	Citronellol	C ₁₀ H ₂₀ O	1221	1221	-	-	-	0.06	RI, MS
21	17.25	β -Cyclohomocitral	C ₁₁ H ₁₈ O	1248	1251	0.11	-	-	-	RI, MS
22	17.36	2,4-Dimethylundecane	C ₁₃ H ₂₈	1252	1253	-	-	0.35	-	RI, MS
23	17.82	3-Methyldodecane	C ₁₃ H ₂₈	1268	1270	-	0.11	1.02	-	RI, MS
24	18.045	Borneol acetate	C ₁₂ H ₂₀ O ₂	1277	1277	1.24	0.73	-	0.13	RI, MS
25	18.205	Dihydroedulan IIA	C ₁₃ H ₂₂ O	1282	1284	0.97	-	0.73	0.97	RI, MS
26	19.145	2,3,5,8-Tetramethyldecane	C ₁₄ H ₃₀	1315	1318	-	-	0.31	-	RI, MS
27	19.215	E-Methyl geranate	C ₁₁ H ₁₈ O ₂	1317	1315	-	-	-	0.05	RI, MS
28	19.26	IsoDihydrocarveol acetate	C ₁₂ H ₂₀ O ₂	1319	1322	0.62	-	-	-	RI, MS
29	19.575	δ -Elemene	C ₁₅ H ₂₄	1327	1327	0.3	0.11	-	0.09	RI, MS
30	19.92	α -Cubebene	C ₁₅ H ₂₄	1342	1342	1.48	0.4	0.32	0.19	RI, MS
31	20.05	1,1,6-Trimethyl-1,2-dihydronaphthalene	C ₁₃ H ₁₆	1345	1344	0.21	-	-	-	RI, MS
32	20.24	<i>cis</i> -Carvyl acetate	C ₁₂ H ₁₈ O ₂	1353	1352	0.35	-	-	-	RI, MS
33	20.4	Cyclosativene	C ₁₅ H ₂₄	1359	1358	0.72	0.14	0.29	0.09	RI, MS
34	20.68	α-Copaene	C ₁₅ H ₂₄	1368	1368	15.49	4.38	5.66	2.25	RI, MS
35	20.86	(E)- β -Damascenone	C ₁₃ H ₁₈ O	1374	1380	0.87	-	0.27	-	RI, MS
36	21.1	β-Elemene	C ₁₅ H ₂₄	1384	1384	2.26	0.73	0.44	5.55	RI, MS
37	21.545	<i>cis</i> - β -Caryophyllene	C ₁₅ H ₂₄	1398	1400	0.38	-	2.05	0.49	RI, MS
38	21.75	5,5-Diethylundecane	C ₁₅ H ₃₂	1406	1408	-	-	0.26	-	RI, MS
39	21.925	E-β-caryophyllene	C ₁₅ H ₂₄	1410	1411	14.42	5.55	5.17	10.21	RI, MS
40	22.095	α -Ionone	C ₁₃ H ₂₀ O	1420	1420	0.68	-	-	0.46	RI, MS
41	22.225	γ -Elemene	C ₁₅ H ₂₄	1425	1425	-	-	-	0.19	RI, MS
42	22.34	Aromadendrene	C ₁₅ H ₂₄	1429	1429	0.35	-	-	-	RI, MS
43	22.37	α -Guaiene	C ₁₅ H ₂₄	1430	1433	-	-	-	0.53	RI, MS
44	22.635	Nerylacetone	C ₁₃ H ₂₂ O	1440	1445	0.87	0.22	-	-	RI, MS
45	22.815	α-Humulene	C ₁₅ H ₂₄	1445	1445	5.96	2.49	3.19	6.9	RI, MS
46	22.95	Neoclovene	C ₁₅ H ₂₄	1453	1453	0.33	-	-	-	RI, MS
47	23.11	2,5-di-tert-Butyl- <i>p</i> -quinone	C ₁₄ H ₂₀ O ₂	1459	1466	-	-	-	0.31	RI, MS
48	23.295	γ -Gurjunene	C ₁₅ H ₂₄	1467	1467	1.06	-	1.04	1.34	RI, MS
49	23.53	Germacrene D	C ₁₅ H ₂₄	1473	1473	1.08	1.53	-	5.01	RI, MS
50	23.54	2-Methyl tetradecane	C ₁₅ H ₃₂	1476	1467	-	-	0.53	-	RI, MS
51	23.6	3-Methyl tetradecane	C ₁₅ H ₃₂	1479	1472	-	0.31	2.82	-	RI, MS
52	23.68	β -Selinene	C ₁₅ H ₂₄	1482	1482	2.16	-	-	2.01	RI, MS

Table 1 (continued)

Peak no.	Rt	Compound	Mo- lecular formula	RI _{exp}	RI _{lit}	Content (%)				Iden- tifica- tion
						Summer	Autumn	Winter	Spring	
53	23.95	Bicyclogermacrene	C ₁₅ H ₂₄	1492	1492	4.89	2.84	1.58	5.57	RI, MS
54	24.025	α -Farnesene	C ₁₅ H ₂₄	1495	1496	-	1.5	-	-	RI, MS
55	24.085	δ -Guaiene	C ₁₅ H ₂₄	1497	1500	0.32	-	-	1.18	RI, MS
56	24.28	2,4-di- <i>t</i> -Butylphenol	C ₁₄ H ₂₂ O	1505	1502	-	-	0.47	0.45	RI, MS
57	24.37	γ -Cadinene	C ₁₅ H ₂₄	1509	1509	0.25	-	-	0.42	RI, MS
58	24.595	δ -Cadinene	C ₁₅ H ₂₄	1514	1514	4.93	1.86	2.46	4.04	RI, MS
59	24.825	Cadine-1,4-diene	C ₁₅ H ₂₄	1524	1524	0.07	-	-	0.24	RI, MS
60	24.81	2-Methyl pentadecane	C ₁₆ H ₃₄	1526	1533	-	-	0.67	-	RI, MS
61	24.965	α -Cadinene	C ₁₅ H ₂₄	1532	1533	-	-	-	0.25	RI, MS
62	25.12	α -Calacorene	C ₁₅ H ₂₀	1535	1536	0.17	-	-	0.34	RI, MS
63	25.255	Elemol	C ₁₅ H ₂₆ O	1543	1543	-	-	-	0.27	RI, MS
64	25.375	Ledol	C ₁₅ H ₂₆ O	1548	1549	0.2	-	-	0.5	RI, MS
65	25.52	E-Nerolidol	C ₁₅ H ₂₆ O	1554	1554	-	0.8	-	1.81	RI, MS
66	25.87	1,3,7,11-Tridecatetraene, 4,8,12-trimethyl-, (3E,7E)	C ₁₆ H ₂₆	1567	1573	-	-	-	0.28	RI, MS
67	26.05	Spathulenol	C ₁₅ H ₂₄ O	1570	1570	0.3	1.75	-	0.86	RI, MS
68	26.17	Caryophyllene oxide	C ₁₅ H ₂₄ O	1575	1575	3.32	1.28	1.12	6.27	RI, MS
69	36.375	Globulol	C ₁₅ H ₂₄ O	1584	1584	0.47	-	-	0.6	RI, MS
70	26.544	Humulene epoxide I	C ₁₅ H ₂₄ O	1594	1593	-	-	-	0.22	RI, MS
71	26.66	Virdiflorol	C ₁₅ H ₂₆ O	1598	1598	-	-	-	0.39	RI, MS
72	26.8	Humulene epoxide II	C ₁₅ H ₂₄ O	1604	1604	0.82	0.46	0.4	1.48	RI, MS
73	27.095	Hexadecane	C ₁₆ H ₃₄	1617	1600	-	-	0.31	-	RI, MS
74	27.225	1- <i>epi</i> -Cubanol	C ₁₅ H ₂₆ O	1622	1625	-	-	-	0.39	RI, MS
75	27.553	τ -Cadinol	C ₁₅ H ₂₆ O	1637	1637	-	-	-	0.93	RI, MS
76	27.65	δ -Cadinol	C ₁₅ H ₂₆ O	1641	1641	-	-	-	0.42	RI, MS
77	28.118	1-Heptadecene	C ₁₇ H ₃₄	1661	1673	-	-	-	0.59	RI, MS
78	28.14	Hexadecane, 2-methyl	C ₁₇ H ₃₆	1662	1666	-	-	0.21	-	RI, MS
79	28.28	14-Hydroxy-9- <i>epi</i> -(E)-caryophyllene	C ₁₅ H ₂₄ O	1668	1668	-	-	-	0.6	RI, MS
80	28.545	3-Methyl hexadecane	C ₁₇ H ₃₆	1680	1677	-	-	0.28	-	RI, MS
81	28.628	Heptadecane	C ₁₇ H ₃₆	1684	1700	-	-	0.32	0.57	RI, MS
82	28.835	6,6-Diethyltetradecane	C ₁₈ H ₃₈	1692	1695	-	-	0.98	-	RI, MS
83	29.055	1-Pentadecanal	C ₁₅ H ₃₀ O	1702	1702	-	-	-	0.06	RI, MS
84	29.82	7-Methyl heptadecane	C ₁₈ H ₃₈	1735	1745	-	-	0.38	-	RI, MS
85	29.84	Mintsulfide	C ₁₅ H ₂₄ S	1736	1741	-	-	-	0.21	RI, MS
86	30.1	α -Cyperone	C ₁₅ H ₂₂ O	1748	1746	-	-	-	0.25	RI, MS
87	30.225	4-Methyl heptadecane	C ₁₈ H ₃₈	1753	1749	-	-	-	0.06	RI, MS
88	30.858	Octadecane	C ₁₈ H ₃₈	1780	1800	-	-	-	0.41	RI, MS
89	31.055	Phytane	C ₂₀ H ₄₂	1789	1795	-	-	-	0.12	RI, MS
90	31.315	Hexadecanal	C ₁₆ H ₃₂ O	1800	1800	-	-	-	0.07	RI, MS
91	31.835	Hexahydrofarnesyl acetone	C ₁₈ H ₃₆ O	1828	1825	0.23	0.28	0.39	0.47	RI, MS
92	32.9	Nonadecane	C ₁₉ H ₄₀	1880	-	-	-	0.31	0.25	MS only
93	33.59	Palmitic acid methyl ester	C ₁₇ H ₃₄ O ₂	1909	1910	3.16	0.25	-	1.05	RI, MS
94	34.37	Palmitic acid	C ₁₆ H ₃₂ O ₂	1947	1946	-	3.39	-	0.13	RI, MS
95	35.0	3-Methyl nonadecane	C ₂₀ H ₄₂	1977	1974	-	-	0.84	0.36	RI, MS
96	35.5	Octadecanal	C ₁₈ H ₃₆ O	2001	2010	-	-	-	0.06	RI, MS
97	35.55	Verticilla-4(20),7,11-triene	C ₂₀ H ₃₂	2004	2004	-	0.29	-	-	RI, MS
98	36.88	Methyl octadeca-9,12-dienoate	C ₁₉ H ₃₄ O ₂	2076	2075	1.2	-	-	-	RI, MS
99	36.93	3-Methyleicosane	C ₂₁ H ₄₄	2079	2072	-	0.25	1.77	0.55	RI, MS
100	37.06	Oleic acid methyl ester	C ₁₉ H ₃₆ O ₂	2086	2086	2.88	-	-	0.6	RI, MS
101	37.335	<i>trans</i> -Phytol	C ₂₀ H ₄₀ O	2101	2103	0.59	1.13	0.62	5.2	RI, MS
102	37.435	Heneicosane	C ₂₁ H ₄₄	2107	2100	-	-	0.28	-	RI, MS
103	37.46	Methyl stearate	C ₁₉ H ₃₈ O ₂	2108	2109	0.25	-	-	-	RI, MS

Table 1 (continued)

Peak no.	Rt	Compound	Molecular formula	RI _{exp}	RI _{lit}	Content (%)				Identification
						Summer	Autumn	Winter	Spring	
104	37.615	5-Ethyl-5-methylnonadecane	C ₂₂ H ₄₆	2117	2111	-	-	0.59	-	RI, MS
105	37.81	Oleic acid	C ₁₈ H ₃₄ O ₂	2127	2120	-	0.47	-	-	RI, MS
106	38.22	5-Methyl heneicosane	C ₂₂ H ₄₆	2150	2151	-	-	0.25	0.06	RI, MS
107	38.282	Isoincensole	C ₂₀ H ₃₄ O ₂	2153	2152	-	1.49	-	-	RI, MS
108	38.73	3-Methyl heneicosane	C ₂₂ H ₄₆	2178	2175	0.21	-	3	0.44	RI, MS
109	40.5	3-Methyl docosane	C ₂₃ H ₄₈	2276	2275	0.36	0.41	3.7	0.79	RI, MS
110	42.2	2-Methyl tricosane	C ₂₄ H ₅₀	2369	2365	0.26	0.32	2.92	0.53	RI, MS
111	42.86	3,11-Dimethyl tricosane	C ₂₅ H ₅₂	2405	2405	-	-	-	0.05	RI, MS
112	43.9	3-Methyl tetracosane	C ₂₅ H ₅₂	2472	2473	0.51	0.8	2.99	1.34	RI, MS
113	45.49	3-Methyl pentaacosane	C ₂₆ H ₅₄	2574	2573	0.14	0.19	1.26	0.49	RI, MS
114	47.015	3-Methyl hexacosane	C ₂₇ H ₅₆	2672	2672	0.27	0.74	1.37	0.98	RI, MS
115	48.46	2-Methyl heptacosane	C ₂₈ H ₅₈	2765	2761	-	0.36	0.24	0.22	RI, MS
116	49.0	Squalene	C ₃₀ H ₅₀	2800	2808	-	0.27	0.42	0.14	RI, MS
117	49.875	2-Methyl octacosane	C ₂₉ H ₆₂	2856	2858	0.19	1.73	0.75	0.48	RI, MS
118	51.255	7-Methyl nonacosane	C ₃₀ H ₆₂	2944	2945	-	-	-	0.08	RI, MS
119	51.725	Campesterol	C ₂₈ H ₄₈ O	2974	-	-	1.72	-	-	MS only
120	51.99	24-Norursa-3,9(11),12-triene	C ₂₉ H ₄₄	2991	-	-	2.45	-	-	MS only
121	52.185	24-Norursa-3,12-diene	C ₂₉ H ₄₆	3004	-	-	6.01	-	-	MS only
122	52.83	24-Noroleana-3,12-diene	C ₂₉ H ₄₆	3045	3057	-	12.92	-	-	RI, MS
123	52.97	Stigmasta-3,5-diene	C ₂₉ H ₄₈	3054	-	-	9.58	-	-	MS only
124	56.39	γ-Sitosterol	C ₂₉ H ₅₀ O	3274	3290	-	0.6	-	-	RI, MS
125	56.82	24-Norursa-3,12-dien-11-one	C ₂₉ H ₄₄ O	3301	3351	-	3.75	-	-	MS only
Monoterpene hydrocarbons						18.79	9.13	39.25	0.32	
Oxygenated Monoterpene						2.49	0.73	-	0.86	
Sesquiterpene hydrocarbons						56.62	21.53	22.2	46.89	
Oxygenated Sesquiterpene						5.34	4.57	1.91	15.46	
Diterpene hydrocarocarbons						0.59	2.91	0.62	5.32	
Non-terpenic compounds						1.94	5.22	29.92	8.53	
Non-terpenic oxygenated compounds						8.02	4.11	-	2	
Others						2.73	37.3	1.89	2.54	
Total % identified						96.52	85.5	95.79	81.92	

The names of the components are in order of their elution from the Rtx-5MS column

Identification was based on comparison of the compounds' mass spectral data (MS) and retention indices (RI) with those of NIST Mass Spectral Library (2017), Wiley Registry of Mass Spectral Data 8th edition and Adams

hydrocarbons present in all seasons' volatile oils. On the other hand, few compounds were detected only in a specific season. For example, γ -elemene (0.19%) and α -guaiene (0.53%) were detected in spring volatile oil only, meanwhile, aromadenderene (0.35%) was detected in summer volatile oil only. Our results were in accordance with the reported data in literature. For instance, *P. suberosa* leaf oil was reported to contain bicyclgermacrene (26.26%) and (E)- β -caryophyllene (7.79%) as the predominant constituents of the leaf oil [12]. The volatile oils of *P. harmandii*, *P. suaveolens*, and *P. longifolia var pendula* leaves contained major sesquiterpene hydrocarbons such as bicyclgermacrene (20.9%), α -humulene (34.2%), and E- β -caryophyllene (30%), respectively [34].

Monoterpene hydrocarbons were the second most abundant class of compounds, with the highest concentration detected in winter volatile oil sample (39.25%) and the least concentration detected in spring volatile oil (0.32%). D-limonene was the most abundant compound of this class with concentrations of 2.63, 0.74, 24.7 and 0.07% in summer, autumn, winter, and spring, respectively. β -Pinene was detected with the highest concentration in summer volatile oil (8.59%) and the least concentration in spring volatile oil (0.14%). Monoterpenes were detected in *P. suaveolens* stem bark in small amount accounting for 2.2% of the total oil composition [35]. However, they weren't detected in *P. sumatrana*, *P. stenopetalla*, *P. cauliflora*, and *P. rumphii* essential oils. The difference of the chemical composition among




Fig. 1 Structures of the major components identified in *P. suberosa* leaf volatile oil in different seasons

Polyalthia species could be due to the different stages of development, extraction procedures, and specific region where the plant was harvested [33].

Non-terpenic compounds represented 1.94–29.92% of the total volatile oil composition, with the highest concentration found in winter volatile oil sample (29.92%), followed by spring volatile oil (8.53%), then autumn volatile oil (5.22%), and the least concentration was detected in summer volatile oil (1.94%). 3-methyl heneicosane (0.21–3%) and 3-methyl tetracosane (0.51–2.99%) were the most abundant compounds of this class. Oxygenated sesquiterpenes represented 1.91–15.46% of the total volatile oil composition. Spring volatile oil exhibited the highest concentration (15.46%), meanwhile, winter

volatile oil exhibited the least concentration (1.91%). The most abundant compound in this class was caryophyllene oxide (1.12–6.27%). Previous study on *P. michaelii* leaves essential oil revealed that the major compound was spathulenol (42.2%) [34].

Non-terpenic oxygenated compounds were detected in three seasons only, their concentrations were 8.02, 4.11, and 2% in summer, autumn, and spring volatile oils, respectively. Long chain aldehydes, esters and acids were detected, such as nonanal (C₉, present in summer and spring volatile oils), oleic acid (present in autumn volatile oil), and palmitic acid, methyl ester (present in summer, autumn, and spring volatile oils).




Fig. 2 Bar chart of *P. suberosa* volatile constituents in four different seasons




Fig. 3 Seasonal variation of phytochemical classes observed in *P. suberosa* volatile oils

Diterpenic hydrocarbons represented 0.59 to 5.32% of the total volatile oil composition. Four compounds were detected phytane, phytol, isoincensole, and verticilla-4(20),7,11-triene. Oxygenated monoterpenes were detected in summer (2.49%), autumn (0.73%), and spring (0.86%) volatile oils only. Borneol acetate (0.13–1.24%) was the most abundant member of this class. The last group contained a variety of classes such as α -ionone and (E)- β -damascenone (norisoprenoids, which are produced by oxidative cleavage of carotenoids and are responsible of the aroma of plants such as tobacco [36]). Sterols were also identified as γ -sitosterol and campesterol. Sterols were previously detected in family Annonaceae [37].

Previous study reported that *P. sessiliflora* stem oil contained eugenol as the predominant compound with a concentration of 42.7% of the total oil composition. It may be possible to postulate that every species has its own compositional pattern [34].

These findings corroborate the idea that seasonal variation can cause the variation of the composition of volatile oil and affect the oil yield [38]. Several factors can lead to the variation in the essential oil content and its composition, such as light, temperature, reproductive stage, season, and the growing conditions which is in accordance with results reported before [26, 39, 40]. From our findings, we have deduced that seasonal variation can cause

alterations in both yield and chemical composition of the tested sample; the highest yield season was spring and the best season for volatile oil production.

Acetylcholinesterase inhibitory activity

Medicinal plants and their essential oils have been a prominent source for various activities such as enzyme inhibition as a safer option than synthetic drugs [26, 41, 42]. *Polyalthia* essential oils have been reported to exert numerous biological activities including; cytotoxic [12, 43], antimicrobial [12, 44, 45], anti-inflammatory [43], and insecticidal activities [46].

Alzheimer's disease (AD), a progressive neurodegenerative disorder, that affects the older and pre-elderly population. This neurological disorder issues from a shortage of acetylcholine (ACh) and is described by exacerbated brain tissue degeneration [47].

Acetylcholine, a neurotransmitter released by cholinergic neurons in synaptic gaps, is involved in memory and learning behaviors. Its decrease has been related to AD [48]. Inhibition of AChE, a cholinergic enzyme found at postsynaptic neuromuscular junctions that breaks down ACh into acetic acid and choline [49], can increase the level of acetylcholine in the brain alleviating the symptoms of the disease and improving cognitive function [50].

To the best of our knowledge, the AChE inhibitory activity of PSLO has never been reported before. However, some alkaloids isolated from *P. stenopetala* and *P. sumatrana* inhibited AChE with percentage inhibition values ranging from 40.2 to 80.6% [51, 52].

The percentage inhibition of 10 µg/mL and 100 µg/mL of PSLO were $16.15 \pm 2.17\%$ and $51.44 \pm 2.8\%$, respectively (Table 2). The inhibitory activity of different concentrations of standard (Donepezil) and essential oil is summarized in supplementary information (Fig. S2).

According to Taqui et al. [53], plant extracts/fractions which have AChE inhibitory activity were classified into three categories based on their IC_{50} values: high potency, $IC_{50} < 20$ µg/mL; moderate potency, $20 < IC_{50} < 200$ µg/mL; and low potency, $200 < IC_{50} < 1000$ µg/mL. PSLO

showed moderate potency against AChE with IC_{50} value of 91.94 µg/mL as shown in Table 2.

The anti-AChE activity of the tested oil may be attributed to the synergistic effect of its components, especially monoterpenes and sesquiterpenes. It has been reported that essential oils containing monoterpenes had the tendency to exhibit good AChE inhibitory effect [54]. D-Limonene was reported to exhibit potent AChE inhibition activity with IC_{50} value of 3.54 mM [55]. α -Pinene showed a strong AChE inhibitory activity with IC_{50} value of 0.022 mg/mL, meanwhile, α -terpineol showed a weak activity with IC_{50} value of 1.3 mg/mL [56]. Linalool and γ -terpinene exhibited weak inhibition of AChE [57]. In addition, several compounds were reported to exhibit anti-cholinesterase activity such as camphene [58], *p*-cymene [59], β -pinene, 2-carene, terpinolene, linalool [60], and sabinene [61]. A study showed that the effect of administration of myrcene, a monoterpene, alone or with donepezil significantly reversed the neurodegenerative effects of $AlCl_3$ and D-galactose in mice, where myrcene enhanced the cholinergic activity and reduced neuroinflammation [62].

Liu et al. studied the interactions between the individual volatile components on AChE inhibition. The study showed that α -terpinolene displayed synergistic effect with sabinene, limonene, and α -pinene. Sabinene had synergistic effects with both limonene and 4-terpineol [63].

It was reported that essential oils containing mainly sesquiterpenes compared to the oils containing monoterpenes were more potent inhibitors of AChE activity, and the same was observed in the case of mixtures dominated by sesquiterpenes where they showed stronger inhibition than mixture dominated by monoterpenes [64]. For instance, a study reported that a combination of (E)- β -caryophyllene, α -pinene, and α -humulene (31:17:10) exhibited more potent inhibitory activity with IC_{50} value of 25 µg/mL compared to the *G. bicolor* leaf oil IC_{50} value of 85 µg/mL which contained the three major volatile components. Meanwhile, the stem oil of the *G. bicolor* containing α -pinene, β -pinene, and (E)- β -caryophyllene showed inhibitory activity with IC_{50} value of 92 µg/mL. A mixture of α -pinene, β -pinene, and (E)- β -caryophyllene (61:14:5) was more potent at inhibiting AChE activity than the stem oil [65].

α -Copaene, E- β -caryophyllene, α -humulene, and α -farnesene were reported to exhibit moderate AChE inhibitory activity [50]. Farnesene was reported to possess neuroprotective effect *via* significantly ameliorating the cytotoxicity of β -amyloid peptides and decreasing AChE activity [66].

Bonesi et al. reported that *trans*-caryophyllene inhibited AChE with a percentage of 32% at 0.06mM [61]. An in-vivo study showed that germacrene D significantly

Table 2 Acetylcholinesterase inhibitory effect of *P. suberosa* leaf volatile oil

Sample	AChE inhibitory activity (%) *		IC_{50} **
	10 µg/mL	100 µg/mL	
PSLO	$16.15 \pm 2.17\%$	$51.44 \pm 2.8\%$	91.94 µg/mL
Donepezil	-	-	9.228 nM

PSLO: *P. suberosa* leaf volatile oil

All determinations are carried out in triplicate manner, and the values are represented as mean \pm SD

* Percentage inhibition calculated as previously mentioned in experimental section

** Concentration of sample used to inhibit 50% of acetylcholinesterase under the test conditions

Table 3 Free binding energies (ΔG) of the major identified compounds in *Polyalthia suberosa* leaf essential oil within the active sites of human acetylcholinesterase using molecular docking and expressed in Kcal/mol. Positive values indicate unfavorable interaction

Compound name	C-Docker Energy ΔG (Kcal/mol)
1 Palmitic acid	-52.6742
2 Donepezil (4EY7, co-crystallized inhibitor)	-28.9953
3 Phytol	-23.4315
4 <i>p</i> -Cymene	-21.6335
5 Caryophyllene oxide	-5.84702
6 β -Pinene	-0.384704
7 α -Copaene	1.72951
8 α -Pinene	1.93741
9 α -Terpineol	4.63067
10 Linalool	4.74992
11 Germacrene D	7.36147
12 Myrcene	9.10231
13 <i>E</i> - β -Caryophyllene	9.58014
14 Viridiflorol	12.5957
15 2-Carene	13.0745
16 Elemol	14.3889
17 D-limonene	16.8749
18 β -Elemene	18.5104
19 Bicyclogermacrene	21.889
20 γ -Terpinene	22.0405
21 α -Farnesene	27.5747
22 Terpinolene	32.4463
23 Camphene	43.5986
24 α -Humulene	49.2467
25 γ -Sitosterol	68.1062
26 Squalene	90.07
27 24-Noroleana-3,12-diene	161.718

inhibited AChE in rat brain structures with percentage over 50% [67]. α -Copaene showed strong synergism combined with both (*E*)- β -caryophyllene and α -humulene [54].

Other compounds also were reported to possess promising AChE inhibitory activity such as viridiflorol and elemol that strongly inhibited AChE with IC_{50} values of 25 and 34 $\mu\text{g/mL}$, respectively [68]. Caryophyllene oxide showed strong AChE inhibitory activity [69]. Phytol improved cognitive functions in scopolamine-induced AD in rats by inhibiting AChE and butyrylcholinesterase enzyme [70]. Palmitic acid and squalene showed inhibition of AChE using TLC bio-autography assay [71].

The biological activity of the essential oil is due to the chemical complexity of the essential oil and the contribution of its individual constituents, since each constituent of this complex is included in the overall activity or may modulate the effects of the other constituents [72]. In this sense, we suggest further studies to isolate the oil




Fig. 4 Validation of the docking protocol

components and test their AChE inhibitory activity as individuals.

These findings suggest a synergistic effect between different compounds identified in PSLO with higher contribution of certain components to this activity [63, 65], thus highlighting the use of the isolated oil as an adjuvant therapy in treatment of Alzheimer's disease [73].

In-silico molecular docking study

Molecular docking study

PSLO exhibited notable AChE inhibitory activity; thus, an *in-silico* molecular docking study was carried out to corroborate the attained results. The human acetylcholinesterase crystal structure was obtained from the Protein Data Bank (<http://www.rcsb.org/pdb/>) complexed with donepezil (PDB ID 4EY7; 2.35 Å). Donepezil, the co-crystallized ligand, was utilized to identify the amino acid residues in the active site of acetylcholinesterase enzyme. The computed free binding energies ΔG (Kcal/mol) of major compounds found in PSLO were displayed in Table 3. Furthermore, the docking parameters were validated by re-docking the co-crystallized ligand into the active site of acetylcholinesterase. The calculated RMSD value between the co-crystallized ligand and the docked pose was 0.32 Å indicating the validity of the docking protocol (Fig. 4).

Palmitic acid, phytol, *p*-cymene, and caryophyllene oxide showed the best affinity and fitting (Supplementary information Fig. S3), displaying free binding energy values of -52.6742, -23.4315, -21.6335, and -5.84702 Kcal/mol, respectively, with palmitic acid exceeding the value of the standard drug donepezil which exhibited ΔG equals to -28.9953 Kcal/mol.

AChE active site, located at the centre bottom of the enzyme molecule, is a 20 Å deep gorge. The active site consists of several subsites. These important sites and residues are catalytic triad (Ser203, His447, Glu334), anionic subsite (Trp86, Tyr133, Glu202, Gly448, Ile451), oxyanion hole (Gly121, Gly122, Ala204), acyl binding pocket (Trp236, Phe295, Phe297, Phe338) and peripheral anionic subsite (Asp74, Tyr124, Ser125, Trp286, Tyr337, Tyr341) [74].

The high fitting scores of these compounds within the active site of AChE can be clarified by their agreeable binding through the formation of various bonds. Palmitic acid formed one conventional hydrogen bond with Gly120. Meanwhile, phytol formed two conventional hydrogen bonds with Tyr133 and Glu202 and six π -alkyl bonds with Trp86, Tyr337, Phe338, Tyr341, and Tyr72. *p*-Cymene formed four π -alkyl bonds with Phe338, Tyr337, and Tyr341 in addition to one π -lone pair bond with Tyr124. Caryophyllene oxide formed one π - δ bond with Trp86 and six π -alkyl bonds with Trp86, His447, Phe297, and Phe338. Donepezil, the co-crystallized inhibitor, was used as the reference acetylcholinesterase inhibitor drug and formed two hydrogen-water bonds with HOH253, one conventional hydrogen bond with Phe295, two π -alkyl bonds with Tyr337 and Tyr341, two π - δ bonds with Tyr341 and Phe338, three π - π bonds with Trp86, Trp286, and Tyr34, and three hydrogen-carbon bonds with Ser293 and Tyr341. Noteworthy, all these compounds exhibited Van der Waals forces with the amino acid residues present in the active binding site of AChE.

ADMET

The aim of ADMET prediction, an important step in pharmaceutical R&D development, is to explore the drug-like properties of the identified compounds in PSLO. As shown in supplementary information (Table

S1), most of the identified compounds in PSLO displayed very high and high penetration through blood brain barrier (BBB) which is important for the inhibition of AChE in the brain except for phytol, squalene, 24-noroleana-3,12-diene, and γ -sitosterol. Most compounds showed good and moderate intestinal absorption except phytol, squalene, 24-noroleana-3,12-diene, and γ -sitosterol. The compounds exhibited a range of water solubility varying from very poor solubility to good solubility.

Few compounds such as 24-noroleana-3,12-diene, α -copaene, camphene, caryophyllene oxide, *E*- β -caryophyllene, and γ -sitosterol exhibited certain hepatotoxicity. Fortunately, all the compounds were non-inhibitors for CYP2D6 except donepezil and germacrene D, thus, no drug-drug or drug-herb interactions would be encountered. However, most of the compounds exhibited plasma protein binding (PPB) leading to a decrease in free plasma fraction thus a decrease in the volume of distribution and decreasing the concentration of the drug at the site of action.

Those results are shown in ADMET plot (Fig. 5), where all compounds showed excellent intestinal absorption and blood-brain barrier penetration, as evidenced by their allocation in the 99% absorption ellipse. Concomitantly, phytol, squalene, 24-noroleana-3,12-diene, and γ -sitosterol that showed poor intestinal absorption and an undefined BBB penetration were positioned outside the 99% absorption ellipse.




Fig. 5 ADMET Plot for bioactive metabolites identified in *P. suberosa* leaf essential oil displaying 95% and 99% confidence limit ellipses corresponding to blood-brain barrier (BBB) and human intestinal absorption models

Conclusion

Chemical profiling of the *P. suberosa* leaf volatile oils obtained in four different seasons unveiled that the composition and yield of the oil were varied according to seasonal changes. PSLO showed moderate acetylcholinesterase inhibition, this may be due to synergism between certain components of the oil. *In-silico* molecular docking unveiled that palmitic acid, phytol, *p*-cymene, and caryophyllene oxide demonstrated the best fitting scores within the active sites of human acetylcholinesterase enzyme. To the best of our knowledge, this is the first study to highlight the promising use of *P. suberosa* leaf essential oil as an adjuvant therapy in the management of Alzheimer's disease. Further *in-vivo* neuroprotective investigations and validation of the isolated essential oil are recommended.

Abbreviations

ACh	Acetylcholine
AChE	Acetylcholinesterase enzyme
AD	Alzheimer's disease
ADMET	Absorption, distribution, metabolism, excretion, and toxicity
BBB	Blood brain barrier
DMSO	Dimethyl sulfoxide
DTNB	3,3'-dithiodipropionic acid di-(N-hydroxysuccinimide ester)
GC/MS	Gas Chromatography/Mass Spectrometry
PPB	Plasma protein binding
PSLO	<i>P. suberosa</i> leaf essential oil
RMSD	Root mean square deviation
TLC	Thin layer chromatography

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12906-024-04443-z>.

Supplementary Material 1

Acknowledgements

The authors would like to acknowledge the Science and Technology and Innovation fund (STIFA) for funding the research project number: 46667 under the title "sustainability of lab. capacities of center of drug discovery research and development".

Author contributions

OAM: Methodology, Resources and Writing—original draft. IMA: Conceptualization, Methodology, Validation, Supervision and Writing—review & editing. OAE: Conceptualization, Methodology, Validation, Supervision and Writing—review & editing. ABS: Conceptualization, Validation, Supervision and Writing—review & editing.

Funding

Open access funding provided by The Science, Technology & Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB).

Data availability

Data are available upon request from the first author.

Declarations

Ethics approval and consent to participate

All methods were performed in accordance with the relevant guidelines and regulations.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Received: 14 November 2023 / Accepted: 19 March 2024

Published online: 12 April 2024

References

1. Yiannopoulou KG, Papageorgiou SG. Current and future treatments in Alzheimer Disease: an update. *J Cent Nerv Syst Disease*. 2020;12.
2. Naaz H, Singh S, Pandey VP, Singh P, Dwivedi UN. Anti-cholinergic alkaloids as potential therapeutic agents for Alzheimer's disease: an *in silico* approach. *Indian J Biochem Biophys*. 2013;50(2).
3. Duyckaerts C, Delatour B, Potier M-C. Classification and basic pathology of Alzheimer disease. *Acta Neuropathol*. 2009;118(1).
4. Proestos C. The Benefits of Plant Extracts for Human Health. *Foods (Basel Switzerland)*. 2020;9(11).
5. Fahmy NM, Al-Sayed E, El-Shazly M, Singab AN. Comprehensive review on flavonoids biological activities of Erythrina plant species. *Ind Crops Prod*. 2018;123.
6. Sramek JJ, Frackiewicz EJ, Cutler NR. Review of the acetylcholinesterase inhibitor galanthamine. *Expert Opin Investig Drugs*. 2000;9(10).
7. Chen Y-C, Chia Y-C, Huang B-M. Phytochemicals from Polyalthia species: potential and implication on Anti-Oxidant, Anti-Inflammatory, anti-cancer, and Chemoprevention activities. *Molecules*. 2021;26(17).
8. Son NT, Le TA, Thuy DTT, Nguyen DL, Tuyen TT, Hoang Thi MD et al. Essential oils of the Leaf and Stem of Polyalthia Viridis Craib and their biological activities. *Nat Prod Commun*. 2021;16(9).
9. Amin R, Quispe C, Herrera-Bravo J, Rahman M, Novakovic R, Daştan SD et al. Ethnopharmacological-Based Validation of Polyalthia suberosa Leaf Extract in Neurological, Hyperalgesic, and Hyperactive Gut Disorders Using Animal Models. *Evidence-Based Complementary and Alternative Medicine*. 2022;2022.
10. Yasmen N, Aziz MA, Tajmim A, Hazra AK, Rahman SMM, Akter MI. Analgesic and Anti-Inflammatory Activities of Diethyl Ether and n-Hexane Extract of Polyalthia suberosa Leaves. *Evid Based Complement Alternat Med*. 2018;2018.
11. Jayaveera KN, Sridhar C, Kumanan R, Yogananda RK, Tarakaram K, Mahesh M. Phytochemical, antibacterial and anthelmintic potential of flowers of Polyalthia Longifolia. *J Pharm Chem*. 2010;4(2).
12. The SN, Le Tuan A, Thu TDT, Dinh LN, Thi TT. Essential oils of Polyalthia suberosa leaf and twig and their cytotoxic and antimicrobial activities. *Chem Biodivers*. 2021;18(5).
13. Rathore S, Mukhia S, Kapoor S, Bhatt V, Kumar R, Kumar R. Seasonal variability in essential oil composition and biological activity of Rosmarinus officinalis L. accessions in the western Himalaya. *Sci Rep*. 2022;12(1).
14. Hussain AI, Anwar F, Nigam PS, Ashraf M, Gilani AH. Seasonal variation in content, chemical composition and antimicrobial and cytotoxic activities of essential oils from four Mentha species. *J Sci Food Agric*. 2010;90(11).
15. Thabet AA, Ayoub IM, Youssef FS, Al Sayed E, Singab ANB. Essential oils from the leaves and flowers of Leucophyllum frutescens (Scrophulariaceae): phytochemical analysis and inhibitory effects against elastase and collagenase *in vitro*. *Nat Prod Res*. 2022;36(18).
16. Adams RP. Identification of essential oil components by gas chromatography/mass spectrometry. 4th ed. Carol Stream (IL): Allured Publishing Corporation; 2007.
17. Ashmawy AM, Ayoub IM, Eldahshan OA. Chemical composition, cytotoxicity and molecular profiling of Cordia Africana Lam. On human breast cancer cell line. *Nat Prod Res*. 2021;35(21).
18. Younis MM, Ayoub IM, Mostafa NM, El Hassab MA, Eldehna WM, Al-Rashood ST et al. GC/MS profiling, anti-collagenase, anti-elastase, anti-tyrosinase and anti-hyaluronidase activities of a Stenocarpus sinuatus leaves extract. *Plants*. 2022;11(7).
19. Abdelbaset S, El-Kersh DM, Ayoub IM, Eldahshan OA. GC-MS profiling of Vitex pinnata bark lipophilic extract and screening of its anti-TB and cytotoxic activities. *Nat Prod Res*. 2022.
20. Thabet AA, Moghannem S, Ayoub IM, Youssef FS, Al Sayed E, Singab ANB. GC/MS profiling of essential oils from Bontia daphnoides L., chemometric

- discrimination, isolation of dehydroepingaione and evaluation of antiviral activity. *Sci Rep.* 2022;12(1).
21. Saeed Kotb S, Ayoub IM, El-Moghazy SA, Singab ANB. Profiling the lipophilic fractions of *Pithecellobium dulce* Bark and leaves using GC/MS and evaluation of their antioxidant, Antimicrobial and cytotoxic activities. *Chem Biodivers.* 2020;17(7).
 22. Shahat EA, Bakr RO, Eldahshan OA, Ayoub NA. Chemical Composition and Biological activities of the essential oil from leaves and flowers of *Pulicaria incisa* sub. *Candolleana* (family Asteraceae). *Chem Biodivers.* 2017;14(4).
 23. Eldahshan OA, Halim AF. Comparison of the composition and antimicrobial activities of the essential oils of Green Branches and leaves of Egyptian Navel Orange (*Citrus sinensis* (L.) Osbeck var. Malesy). *Chem Biodivers.* 2016;13(6).
 24. Singab AN, Mostafa NM, Eldahshan OA, Ashour ML, Wink M. Profile of volatile components of hydrodistilled and extracted leaves of *Jacaranda acutifolia* and their antimicrobial activity against foodborne pathogens. *Nat Prod Commun.* 2014;9(7).
 25. Abd El-Ghffar EA, El-Nashar HA, Eldahshan OA, Singab AN. GC-MS analysis and hepatoprotective activity of the n-hexane extract of *Acrocarpus fraxinifolius* leaves against Paracetamol-induced hepatotoxicity in male albino rats. *Pharm Biol.* 2017;55(1).
 26. Korany DA, Ayoub IM, Labib RM, El-Ahmady SH, Singab ANB. The impact of seasonal variation on the volatile profile of leaves and stems of *Brownea grandiceps* (Jacq.) With evaluation of their anti-mycobacterial and anti-inflammatory activities. *South Afr J Bot.* 2021;142.
 27. Ellman GL, Courtney KD, Andres V Jr, Featherstone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. *Biochem Pharmacol.* 1961;7(2).
 28. Kia Y, Osman H, Kumar RS, Basiri A, Murugaiyah V. Ionic liquid mediated synthesis of mono- and bis-spirooxindole-hexahydropyridines as cholinesterase inhibitors and their molecular docking studies. *Bioorg Med Chem.* 2014;22(4).
 29. Ayoub IM, George MY, Menze ET, Mahmoud M, Botros M, Essam M et al. Insights into the neuroprotective effects of *Salvia officinalis* L. and *Salvia microphylla* Kunth in the memory impairment rat model. *Food Funct.* 2022;13(4).
 30. Yehia SM, Ayoub IM, Watanabe M, Devkota HP, Singab ANB. Metabolic profiling, antioxidant, and enzyme inhibition potential of *Iris pseudacorus* L. from Egypt and Japan: a comparative study. *Sci Rep.* 2023;13(1).
 31. Ayoub IM, Abdel-Aziz MM, Elhady SS, Bagalagel AA, Malatani RT, Elkady WM. Valorization of *Pimenta racemosa* essential oils and extracts: GC-MS and LC-MS phytochemical profiling and evaluation of *Helicobacter pylori* Inhibitory Activity. *Molecules.* 2022;27(22).
 32. Gad H, Al-Sayed E, Ayoub I. Phytochemical discrimination of *Pinus* species based on GC-MS and ATR-IR analyses and their impact on *Helicobacter pylori*. *Phytochem Anal.* 2021;32(5).
 33. Shakri NM, Salleh WMNH, Khamis S, Ali NAM, Shaharudin SM. Chemical composition of the essential oils of four *Polyalthia* species from Malaysia. *Z für Naturforschung C.* 2020;75:11–2.
 34. Dai DN, Thang TD, Ogunwande IA. Chemical composition of essential oils from the leaves and stem barks of Vietnamese species of *Polyalthia Harmandii*, *Polyalthia jucunda* and *polyalthia thorelii*. *Nat Prod Res.* 2014;28(8).
 35. Nyegue M, Amvam-Zollo P-H, Etoa F-X, Agnani H, Menu C. Chemical and Biological investigations of essential oils from stem barks of *Enantia Chlorantha Oliv.* and *Polyalthia Suaveolens Engler. & Diels.* From Cameroon. *Nat Prod Commun.* 2008;3(7).
 36. Popova V, Ivanova T, Prokopov T, Nikolova M, Stoyanova A, Zhelezkov VD. Carotenoid-Related Volatile compounds of Tobacco (*Nicotiana tabacum* L.) essential oils. *Molecules.* 2019;24:19.
 37. Gyasi JN, Opoku R, Borquaye LS. Chemical Composition, Total Phenolic Content, and Antioxidant Activities of the Essential Oils of the Leaves and Fruit Pulp of *Annona muricata* L. (Soursop) from Ghana. *Biochemistry Research International.* 2019;2019.
 38. Khalid A, El-Gohary A. Effect of seasonal variations on essential oil production and composition of *Plectranthus amboinicus* (Lour.) Grow in Egypt. *Int Food Res J.* 2014;21(5).
 39. Barros LSP, Santos da Cruz EdN, de Araújo Guimarães B, Setzer WN et al. Veras Mourão RH, do Rosário da Silva JK. Chemometric analysis of the seasonal variation in the essential oil composition and antioxidant activity of a new geraniol chemotype of *Lippia alba* (Mill.) N.E.Br. ex Britton & P. Wilson from the Brazilian Amazon. *Biochemical Systematics and Ecology.* 2022;105.
 40. Parki A, Chaubey P, Prakash O, Kumar R, Pant AK, Accessions. *Med (Basel Switzerland).* 2017;4(4).
 41. El-Nashar HAS, Eldehna WM, Al-Rashood ST, Alharbi A, Eskandrani RO, Aly SH. GC/MS Analysis of Essential Oil and enzyme inhibitory activities of *Syzygium cumini* (Pampesia) grown in Egypt: Chemical characterization and molecular Docking studies. *Molecules.* 2021;26(22).
 42. Azab SS, Abdel Jaleel GA, Eldahshan OA. Anti-inflammatory and gastro-protective potential of leaf essential oil of *Cinnamomum glanduliferum* in ethanol-induced rat experimental gastritis. *Pharm Biol.* 2017;55(1).
 43. Son NT, Le TA, Thuy DT, Nguyen DL, Tuyen TT, Hoang Thi MD et al. Essential oils of the Leaf and Stem of *Polyalthia Viridis* Craib and their biological activities. *Nat Prod Commun.* 2021;16(9).
 44. Li X-b, Chen G-y, Song X-p, Han C-r, Shao T-m. composition and antimicrobial activities of essential oil of leaves of *Polyalthia laui* Merr. *Tianran Chanwu Yanjiu Yu Kaifa.* 2012;24(5).
 45. Nyegue MA, Ndoye-Foe F, Etoa F-X, Zollo et P-HA, Menu C. Study of Chemical Composition, Growth Inhibition and Antigerminative Effect of three essential oils from Cameroon on four *Bacillus* strains. *J Essent Oil-Bear Plants.* 2014;17(6).
 46. Orafdiya LO, Kaloustian J, Agbani EO, Portugal H, Adewoyin FB, Wojuola A, et al. Pesticidal and antimicrobial profile of the sesquiterpene leaf essential oil of *Polyalthia longifolia* (Sonn.) Thwaites. *Int J Essent Oil Ther.* 2010;4:1–2.
 47. Elhawary EA, Nilofar N, Zengin G, Eldahshan O. Variation of the essential oil components of *Citrus aurantium* leaves upon using different distillation techniques and evaluation of their antioxidant, antidiabetic, and neuroprotective effect against Alzheimer's disease. *BMC Complement Med Ther.* 2024;24.
 48. Chen ZR, Huang JB, Yang SL, Hong FF. Role of Cholinergic Signaling in Alzheimer's Disease. *Molecules.* 2022;27(6).
 49. McHardy SF, Wang HL, McCowen SV, Valdez MC. Recent advances in acetylcholinesterase inhibitors and reactivators: an update on the patent literature (2012–2015). *Expert opinion on therapeutic patents.* 2017;27(4).
 50. Jyotshna, Srivastava N, Singh B, Chanda D, Shanker K. Chemical composition and acetylcholinesterase inhibitory activity of *Artemisia maderaspatana* essential oil. *Pharm Biol.* 2015;53(11).
 51. Salleh WMNH, Shakri NM, Nafiah MA, Ghani NA, Abed SA, Abdel-Aal A-BM. Secondary metabolites from the stem bark of *Polyalthia stenopetala* (Hook. F. & Thomson) Ridl. and their acetylcholinesterase activity. *Bulletin of Pharmaceutical Sciences Assiut.* 2023;46(1).
 52. Salleh W, Shakri NM, Nafiah MA, Khamis S. Chemical constituents and acetylcholinesterase activity from *Polyalthia sumatrana* (miq.) Kurz. *Latin Amer Appl Res.* 2022;52(1).
 53. Taqui R, Debnath M, Ahmed S, Ghosh A. Advances on plant extracts and phytochemicals with acetylcholinesterase inhibition activity for possible treatment of Alzheimer's disease. *Phytomedicine Plus.* 2022;2(1).
 54. Hung NH, Quan PM, Satyal P, Dai DN, Hoa VV, Huy NG et al. Acetylcholinesterase inhibitory activities of essential oils from Vietnamese traditional Medicinal plants. *Molecules.* 2022;27(20).
 55. Zarrad K, Hamouda AB, Chaieb I, Laarif A, Jemâa JM-B. Chemical composition, fumigant and anti-acetylcholinesterase activity of the Tunisian *Citrus aurantium* L. essential oils. *Ind Crops Prod.* 2015;76.
 56. Dohi S, Terasaki M, Makino M. Acetylcholinesterase inhibitory activity and chemical composition of commercial essential oils. *J Agric Food Chem.* 2009;57(10).
 57. Perry NS, Houghton PJ, Theobald A, Jenner P, Perry EK. In-vitro inhibition of human erythrocyte acetylcholinesterase by *Salvia Lavandulaefolia* essential oil and constituent terpenes. *J Pharm Pharmacol.* 2000;52(7).
 58. Hachlafi NEL, Aanniz T, Menyiy NE, Baaboua AE, Omari NE, Balahbib A et al. In Vitro and in vivo Biological investigations of Camphene and its mechanism insights: a review. *Food Reviews Int.* 2023;39(4).
 59. Miyazawa M, Yamafuji C. Inhibition of acetylcholinesterase activity by tea tree oil and constituent terpenoids. *Flavour Fragr J.* 2006;21(2).
 60. Jankowska M, Rogalska J, Wyszowska J, Stankiewicz M. Molecular targets for components of essential oils in the insect nervous System—A review. *Molecules.* 2018;23(1).
 61. Bonesi M, Menichini F, Tundis R, Loizzo MR, Conforti F, Passalacqua NG et al. Acetylcholinesterase and butyrylcholinesterase inhibitory activity of *Pinus* species essential oils and their constituents. *J Enzyme Inhib Med Chem.* 2010;25(5).
 62. Kumar R, Kumar R, Sharma N, Khurana N. Ameliorative effect of myrcene in mouse model of Alzheimer's disease. *Eur J Pharmacol.* 2021;911.
 63. Liu T-T, Chao LK-P, Hong K-S, Huang Y-J, Yang T-S. Composition and Insecticidal Activity of Essential Oil of *Bacopa caroliniana* and Interactive effects of Individual compounds on the activity. *Insects.* 2020;11(1).

64. Arya A, Chahal R, Rao R, Rahman MH, Kaushik D, Akhtar MF et al. Acetylcholinesterase inhibitory potential of various sesquiterpene analogues for Alzheimer's disease therapy. *Biomolecules*. 2021;11(3).
65. Miyazawa M, Nakahashi H, Usami A, Matsuda N. Chemical composition, aroma evaluation, and inhibitory activity towards acetylcholinesterase of essential oils from *Gynura bicolor* DC. *J Nat Med*. 2016;70(2).
66. Arslan ME, Türkez H, Mardinoğlu A. In vitro neuroprotective effects of farnesene sesquiterpene on alzheimer's disease model of differentiated neuroblastoma cell line. *Int J Neurosci*. 2021;131(8).
67. Formagio ASN, Vilegas W, Volobuff CRF, Kassuya CAL, Cardoso CAL, Pereira ZV et al. Exploration of essential oil from *Psychotria Poeppigiana* as an anti-hyperalgesic and anti-acetylcholinesterase agent: Chemical composition, biological activity and molecular docking. *J Ethnopharmacol*. 2022;296.
68. Miyazawa M, Watanabe H, Umemoto K, Kameoka H. Inhibition of acetylcholinesterase activity by Essential Oils of *Mentha* Species. *J Agric Food Chem*. 1998;46(9).
69. Karakaya S, Yilmaz S, Özdemir Ö, Koca M, Pinar NM, Demirci B et al. A caryophyllene oxide and other potential anticholinesterase and anticancer agent in *Salvia verticillata* subsp. *Amasiaca* (Frey & Bornm.) Bornm. (Lamiaceae). *J Essent Oil Res*. 2020;32.
70. Sathya S, Manogari BG, Thamaraiselvi K, Vaidevi S, Ruckmani K, Devi KP. Phytol loaded PLGA nanoparticles ameliorate scopolamine-induced cognitive dysfunction by attenuating cholinesterase activity, oxidative stress and apoptosis in Wistar rat. *Nutr Neurosci*. 2022;25(3).
71. Abed SA, Sirat HM, Taher M. Tyrosinase inhibition, anti-acetylcholinesterase, and antimicrobial activities of the phytochemicals from *Gynotroches axillaris* Blume. *Pak J Pharm Sci*. 2016;29(6).
72. Gad HA, Ayoub IM, Wink M. Phytochemical profiling and seasonal variation of essential oils of three *Callistemon* species cultivated in Egypt. *PLoS ONE*. 2019;14(7).
73. Benny A, Thomas J. Essential Oils as Treatment Strategy for Alzheimer's Disease: Current and Future Perspectives. *Planta Med*. 2019;85(3).
74. Sari S, Yilmaz M. Acetylcholinesterase inhibition, molecular docking and ADME prediction studies of new dihydrofuran-piperazine hybrid compounds. *Med Chem Res*. 2021;30(11).

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.